Sequoia Financial Advisors LLC Acquires 5,063 Shares of Hologic, Inc. $HOLX

Sequoia Financial Advisors LLC boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 80.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,342 shares of the medical equipment provider’s stock after acquiring an additional 5,063 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Hologic were worth $739,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Farther Finance Advisors LLC lifted its position in Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock valued at $113,000 after acquiring an additional 335 shares in the last quarter. SG Americas Securities LLC lifted its position in Hologic by 116.6% in the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock valued at $594,000 after acquiring an additional 5,172 shares in the last quarter. Blue Trust Inc. lifted its position in Hologic by 26.8% in the 1st quarter. Blue Trust Inc. now owns 7,637 shares of the medical equipment provider’s stock valued at $472,000 after acquiring an additional 1,616 shares in the last quarter. Praxis Investment Management Inc. bought a new position in Hologic in the 1st quarter valued at approximately $240,000. Finally, First American Bank bought a new position in Hologic in the 1st quarter valued at approximately $1,758,000. 94.73% of the stock is owned by institutional investors.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.88% of the stock is owned by company insiders.

Hologic Trading Up 2.0%

NASDAQ:HOLX opened at $69.85 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The firm has a market capitalization of $15.54 billion, a price-to-earnings ratio of 28.98, a price-to-earnings-growth ratio of 2.40 and a beta of 0.63. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The business has a fifty day moving average price of $67.11 and a 200-day moving average price of $63.53.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Stephens reissued an “overweight” rating and set a $78.00 price target on shares of Hologic in a report on Thursday, September 18th. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Morgan Stanley increased their price target on Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. UBS Group increased their price target on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. Finally, Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.15.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.